| RS2069154005 |
MAPK1
|
Health Risk |
Pathogenic |
6 conditions, Noonan syndrome 13 |
| RS2069154121 |
MAPK1
|
Health Risk |
Pathogenic |
6 conditions, Noonan syndrome 13 |
| RS2069191620 |
SCO2
|
Health Risk |
Likely pathogenic |
Cardioencephalomyopathy, fatal infantile |
| RS2069199944 |
PAFAH1B1
|
Health Risk |
Conflicting classifications of pathogenicity |
Lissencephaly due to LIS1 mutation, Lissencephaly due to LIS1 mutation |
| RS2069206788 |
SCO2
|
Health Risk |
Pathogenic |
— |
| RS2069218741 |
SCO2
|
Health Risk |
Pathogenic |
Cardioencephalomyopathy, fatal infantile |
| RS2069219201 |
NLRP7
|
Health Risk |
Likely pathogenic |
Hydatidiform mole, recurrent |
| RS2069226261 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly, Lissencephaly |
| RS2069227227 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly, Lissencephaly |
| RS2069227856 |
PAFAH1B1
|
Health Risk |
Pathogenic |
— |
| RS2069230138 |
SCO2
|
Health Risk |
Pathogenic |
— |
| RS2069240492 |
COL4A3
|
Health Risk |
Likely pathogenic |
Autosomal recessive Alport syndrome, Autosomal recessive Alport syndrome |
| RS2069242131 |
COL4A3
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal recessive Alport syndrome, Autosomal recessive Alport syndrome |
| RS2069271269 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly due to LIS1 mutation, Lissencephaly due to LIS1 mutation |
| RS2069289146 |
TTN
|
Health Risk |
Conflicting classifications of pathogenicity |
Dilated cardiomyopathy 1G, Autosomal recessive limb-girdle muscular dystrophy type 2J |
| RS2069325477 |
NF1
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Hereditary cancer-predisposing syndrome |
| RS2069325872 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069325928 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069326347 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069326534 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069326575 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069326761 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069327013 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069327949 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069328243 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069328472 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069329312 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069329470 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069329774 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069329829 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069330560 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069330719 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069331323 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069331850 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069332805 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069333368 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069334590 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069335393 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069336015 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069336193 |
BPTF
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies |
| RS2069336790 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069336948 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069337096 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069337884 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069338050 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069338262 |
NF1
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Hereditary cancer-predisposing syndrome |
| RS2069338311 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069338793 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069358559 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly, Lissencephaly |
| RS2069359971 |
PAFAH1B1
|
Health Risk |
Conflicting classifications of pathogenicity |
Lissencephaly due to LIS1 mutation, Lissencephaly due to LIS1 mutation |
| RS2069361375 |
COL4A3
|
Health Risk |
Likely pathogenic |
Autosomal recessive Alport syndrome, Autosomal dominant Alport syndrome |
| RS2069361452 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly due to LIS1 mutation, Lissencephaly due to LIS1 mutation |
| RS2069375606 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069376216 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069376426 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069376973 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069377259 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069377278 |
TYMP
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2069378035 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069378463 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069379168 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069380852 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069381058 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069381323 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069382435 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2069382585 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069382639 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069383338 |
TYMP
|
Health Risk |
Likely pathogenic |
— |
| RS2069383586 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069385520 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069385970 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069386536 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069386760 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069386858 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069404553 |
PCCA
|
Health Risk |
Pathogenic |
Propionic acidemia, Propionic acidemia |
| RS2069405903 |
NBEA
|
Health Risk |
Likely pathogenic |
— |
| RS2069418640 |
ATRX
|
Health Risk |
Conflicting classifications of pathogenicity |
Alpha thalassemia-X-linked intellectual disability syndrome, Alpha thalassemia-X-linked intellectual disability syndrome |
| RS2069445752 |
TYMP
|
Health Risk |
Likely pathogenic |
Mitochondrial DNA depletion syndrome 1, Mitochondrial DNA depletion syndrome 1 |
| RS2069446068 |
TYMP
|
Health Risk |
Pathogenic/Likely pathogenic |
Mitochondrial DNA depletion syndrome 1, Mitochondrial DNA depletion syndrome 1 |
| RS2069447812 |
NF1
|
Health Risk |
Likely pathogenic |
— |
| RS2069448326 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069448374 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069448419 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069448473 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069448538 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069448879 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069449497 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069450324 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069451431 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069452094 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069453458 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069454068 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069454362 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2069454402 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069454695 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2069454921 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2069502314 |
TYMP
|
Health Risk |
Pathogenic |
— |
| RS2069504242 |
TYMP
|
Health Risk |
Pathogenic/Likely pathogenic |
Mitochondrial DNA depletion syndrome 1, Mitochondrial DNA depletion syndrome 1 |
| RS2069534941 |
NEB
|
Health Risk |
Pathogenic/Likely pathogenic |
Nemaline myopathy 2, Nemaline myopathy |
| RS2069544 |
MYH7
|
Health Risk |
Pathogenic/Likely pathogenic |
Cardiovascular phenotype, Hypertrophic cardiomyopathy |